CAYLA Patent applications |
Patent application number | Title | Published |
20140242108 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists - A conjugated compound of Formula I: Q-Z—R | 08-28-2014 |
20140141033 | CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS - A conjugated compound of formula Q-Z—R | 05-22-2014 |
20130336996 | NOVEL COMPOSITIONS OF TLR7 AND/OR TLR8 AGONISTS CONJUGATED TO LIPIDS - A conjugated compound of formula Q-Z—R | 12-19-2013 |
20110008894 | LYOPHILIZED PLASMID/DNA TRANSFECTION REAGENT CARRIER COMPLEX - Disclosed is a novel formulation for the production of a lyophilized plasmid/DNA transfection reagent complex capable of serving as a carrier for additional free plasmids. Upon rehydration, this plasmid/DNA transfection reagent carrier can be used to introduce simultaneously the complexed plasmid and the additional free plasmids into animal cells. This novel formulation can be useful for viral particle production, gene transfer experiments like gene silencing experiments, reporter gene, or integration/selection experiments. | 01-13-2011 |
20100222418 | Combination Products For Treating Cancer - The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject. | 09-02-2010 |